Drug intelligence / Profile preview

paclitaxel + carboplatin + epoetin alfa

Development stage: Unknown
Lead developer: Pfizer
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Intravenous, Subcutaneous

Overview

This is a combination therapy consisting of two chemotherapy drugs (paclitaxel and carboplatin) plus an erythropoiesis-stimulating agent (epoetin alfa). The paclitaxel-carboplatin combination destroys rapidly dividing cancer cells and is used to treat various solid tumors including ovarian, lung, and breast cancers. Epoetin alfa is added to prevent or treat chemotherapy-induced anemia by stimulating red blood cell production, reducing the need for blood transfusions and helping maintain quality of life during treatment.

Other names: PC + epoetin alfaCarboTaxol + epoetin alfa

Targets

Erythropoietin ReceptorMicrotubuleDNA

Beyond the preview

Go deeper on paclitaxel + carboplatin + epoetin alfa.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on paclitaxel + carboplatin + epoetin alfa.

Explore the full profile